Category: Mergers and Acquisitions

January 20, 2023

Charles River Laboratories International Inc. and Rznomics Inc., a South Korea-based biopharmaceutical company specialized in the development of RNA-based gene therapeutics, have announced a viral vector contract development and manufacturing organization (CDMO) partnership. Rznomics will leverage Charles River’s viral vector […]

January 19, 2023

Sun Pharmaceutical Industries and Concert Pharmaceuticals, Inc. entered a definitive agreement under which Sun Pharma will acquire Concert through an upfront payment of $576 million. Concert stockholders will also receive up to an additional $3.50 per share of common stock […]

January 19, 2023

CEPI is a partnership between public, private, philanthropic, and civil organisations to develop vaccines against future epidemics and pandemics. The agreement, worth $4.3 million, is the first to be announced as part of CEPI’s call in January 2022 for proposals […]

January 18, 2023

AbbVie and US-based Anima Biotech (Anima) have formed a collaboration to discover and develop messenger RNA (mRNA) biology modulators for three targets across oncology and immunology. In the collaboration, Anima will use its mRNA Lightning technology platform to discover novel […]

January 18, 2023

The takeover comes a few months after Bayer stepped up the digital capabilities of its radiology business with the launch of AI-powered software for X-ray, MRI, and CT imaging under the Calantic Digital Solutions umbrella brand. The launch of Calantic […]

January 17, 2023

Antibodies targeting the protein Claudin18.2, as Flame’s FL-301 does, have been the focus of some biotechnology dealmaking over the past year, involving companies like Turning Point Therapeutics, Elevation Oncology and even AstraZeneca. Claudin18.2 is expressed in gastrointestinal and pancreatic cancers, […]

January 17, 2023

Shares in the company fell sharply this morning after the announcement of the deal, which will see the two companies combine behind lead programme ELI-002, an immunotherapy targeting KRAS-driven cancers that is currently in a phase 1 trial in pancreatic […]

January 13, 2023

Alora Pharmaceuticals announced that its wholly owned subsidiary, Sovereign Pharmaceuticals, has acquired, through bankruptcy proceedings, substantially all of Monarch PCM’s manufacturing capabilities located in Fort Worth, TX. The acquisition, which closed on January 4, 2022, included all of Monarch’s equipment […]

January 11, 2023

The partners will use Anima’s mRNA Lightning platform to discover novel mRNA biology modulators for the collaboration targets, with AbbVie gaining exclusive rights to licence, further develop and commercialise the resulting programmes. In exchange, an upfront payment of $42m will […]

January 10, 2023

The deal, billed as BioNTech’s largest to date and unveiled at the JP Morgan healthcare conference today, includes $362 million upfront with another £200 million on offer if performance targets are met. The two companies have already been working together […]

January 9, 2023

Supported by voting agreements from leading Amryt shareholders and directors, and unanimously approved and recommended by the boards of both companies, the total transaction is worth up to $1.48 billion, with upfront consideration of $1.25 billion representing a 107% premium […]

January 9, 2023

The agreement values Boston-based Albireo at $952 million, with shareholders in the company also in line for another $10-per-share payout in a contingent value right (CVR) if Bylvay (odevixibat) gets approved for a follow-up indication. Albireo secured approval in the […]

January 6, 2023

The cancer immunotherapies will mainly be provided in the context of clinical trials over the alliance, which extends out to 2030, but also covers supply of commercial therapies if approved in the interim. It will also cover some infectious disease […]

January 6, 2023

The acquisition adds multiple clinical and pre-clinical immunology assets to the company’s own immunology pipeline – led by izokibep, a small therapeutic protein inhibitor of interleukin-17A (IL-17A), designed to overcome the limitations of monoclonal antibodies – and includes a potentially […]

January 6, 2023

As part of the agreement, Amgen will be granted rights to utilise Synaffix’s proprietary ADC technologies, GlycoConnect and HydraSpace, as well as select toxSYN linker-payloads for one ADC programme. The company will also have the option to exercise exclusive research […]

January 5, 2023

The deal marks 10-year-old Moderna’s first acquisition. The company develops mRNA therapeutics and vaccines, and the move will enable it to utilise the synthetic biology and enzyme tech of 2018-founded Japanese company OriCiro, which develops cell-free DNA synthesis and amplification […]

January 5, 2023

Fujifilm Cellular Dynamics, a global developer and manufacturer of human induced pluripotent stem cells (iPSC), has entered an agreement to grant Novo Nordisk a non-exclusive right to use its iPSC platform for the development and commercialization of iPSC-derived cell therapies […]

January 4, 2023

Moderna, Inc., a biopharma company developing messenger RNA (mRNA) therapeutics and vaccines, and OriCiro Genomics K.K., a developer of cell-free DNA synthesis and amplification technologies based in Japan, have entered into a definitive agreement under which Moderna will acquire OriCiro […]

January 4, 2023

Neuca Clinical Trials Inc., a holding company held by Neuca Group, the proprietor of Clinscience international CRO, has increased its clinical operations in the U.S. by purchasing a 72.6% stake in OncoBay, a Tampa, Florida-based CRO founded by Moffit Cancer […]

January 4, 2023

The agreement – which focuses on autoimmune diseases lupus and rheumatoid arthritis (RA) – comes almost two years after EVOQ penned a $240 million deal with Amgen that also focused on using the NanoDisc platform for autoimmune disorder therapies. For […]